Q-omics provides the consensus-scored ISCA2 profile across patient tissues and cancer cell-line models. ISCA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ISCA2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ISCA2 RNA expression shows 17,864 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, HNSC, and ACC as cancer lineages where ISCA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISCA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISCA2 survival associations across molecular data types. ISCA2 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISCA2 RNA expression–survival associations across cancer types. High ISCA2 expression shows unfavorable associations in HNSC, but favorable associations in THCA, BRCA, OV, KIRC and MESO. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for ISCA2 RNA expression.
This table summarizes ISCA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ISCA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISCA2 shows lower tumor expression in KIRC and higher tumor expression in HNSC, BLCA, LIHC, LUAD and THCA. The HNSC box plot shows higher ISCA2 RNA expression in tumor versus normal tissue (log2 FC = +0.618, t-test p < 0.001).
This table shows molecular features associated with ISCA2 in patient tissues and cancer cell lines. In patient samples, ISCA2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ISCA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
